-
Founded in:
2000-07-10 -
Country:
China -
Address:
No. 3, Huanan 1st Road, Chongqing (Changshou) Chemical Industry Park -
Tax NO.:
9150011545041127XF -
Registered Funds:
16.085667 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clindamycin palmitate hydrochloride |
Extract from the above information
More
Extract from the above information |
25507-04-4 | 18 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Epinastine hydrochloride |
Extract from the above information
More
Extract from the above information |
80012-44-8 | 18 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Iron saccharate |
Extract from the above information
More
Extract from the above information |
8047-67-4 | 43 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clindamycin phosphate |
A chemically semi-synthesized clindamycin derivative with no antibacterial activity in vitro. It is rapidly hydrolyzed into clindamycin to exert its pharmacological activity after entering the body. Its antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin. It can be administered orally, intramuscularly and intravenously. Its antibacterial effect is 4-8 times stronger than that of lincomycin, with good absorption, high bone concentration and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus, etc.) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, Necrotic Cocci, etc.).
More
A chemically semi-synthesized clindamycin derivative with no antibacterial activity in vitro. It is rapidly hydrolyzed into clindamycin to exert its pharmacological activity after entering the body. Its antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin. It can be administered orally, intramuscularly and intravenously. Its antibacterial effect is 4-8 times stronger than that of lincomycin, with good absorption, high bone concentration and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus, etc.) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, Necrotic Cocci, etc.). |
24729-96-2 | 33 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Mitoxantrone hydrochloride |
No specific pharmacological effects mentioned
More
No specific pharmacological effects mentioned |
70476-82-3 | 17 |